Amicus Therapeutics (FOLD): היקף יתרות המזומנים של החברה

Amicus Therapeutics' transition to a profitable commercial model is evident on the chart: the cash balance history demonstrates financial stability, where the value of 0.29 reflects this status. Growth is driven by patents for the therapy of rare metabolic pathologies. AI molecule screening and line automation enhance efficiency, although clinical trials remain the domain of scientists.
פילוחי מדדים ואנליטיקה של חברת Amicus Pharma (FOLD)

This indicator aggregates the volume of liquid assets and equivalents, allowing for an assessment of the business's ability to fund expansion or cover operational gaps without incurring external debt. For Amicus Therapeutics (FOLD), with its high margins in the orphan drug segment, the cash level confirms financial stability and the capacity to sustain the development of unique medications without the risk of capital degradation.